Key Publications

Byrne JA, Frost S, Chen Y, Bright RK (2014). Tumor protein D52 (TPD52) and cancer – oncogene understudy, or understudied oncogene? Tumour Biol 35: 7369-82

Saletta F, Wadham C, Ziegler DS, Marshall GM, Haber M, McCowage G, Norris MD, and Byrne JA (2014). Molecular profiling of childhood cancer: biomarkers and novel therapies. BBA Clinical 1: 59-77

Saletta F, Seng MS, Lau LMS (2014). Advances in paediatric cancer treatment. Translational Paediatrics 3(2):156-182

Roslan N, Bièche I, Bright RK, Lidereau R, Chen Y, and Byrne JA (2014). TPD52 represents a survival factor in ERBB2-amplified breast cancer cells. Mol Carcinogenesis 53: 807-19

Shahheydari H, Frost S, Smith BJ, Groblewski GE, Chen Y, and Byrne JA (2014). Identification of PLP2 and RAB5C as novel TPD52 binding partners through yeast two-hybrid screening. Mol Biol Rep. 41: 4565-72

Chen Y, Kamili A, Hardy JR, Groblewski GE, Khanna KK, and Byrne JA (2013). Tumor Protein D52 Represents a Negative Regulator of ATM Protein Levels. Cell Cycle 12: 3083-3097

Byrne JA, Chen Y, Martin La Rotta N, Peters GB (2012). Challenges in identifying novel amplification targets in human cancers: chromosome 8q21 as a case study. Genes and Cancer 3: 87-101

Madrid R, Aranda JF, Rodriguez-Fraticelli AE, Ventimiglia L, Andres-Delgado L, Shehata M, Fanayan S, Shahheydari H, Gomez S, Jimenez A, Martin-Belmonte F, Byrne JA, Alonso MA (2010). The formin INF2 regulates basolateral-to-apical transcytosis and lumen formation in association with Cdc42 and MAL2. Dev Cell 18: 814-27